Enveric Biosciences, Inc.
ENVB
$1.27
$0.010.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.07% | 8.19% | 26.16% | 70.43% | 47.47% |
| Total Depreciation and Amortization | -5.15% | -2.37% | -11.48% | -25.87% | -24.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -42.05% | -36.66% | 243.66% | -76.24% | -5.60% |
| Change in Net Operating Assets | 14.01% | 326.29% | 188.14% | -584.61% | 39.63% |
| Cash from Operations | 7.96% | 25.10% | 66.17% | 35.31% | 49.42% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -10.75% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 89.04% | 99.99% | -- | -- |
| Cash from Financing | -33.18% | 349.01% | 593.05% | 103.27% | -- |
| Foreign Exchange rate Adjustments | -148.15% | 45.41% | -39.54% | -93.72% | 140.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -49.52% | 55.99% | 86.11% | 47.93% | 178.81% |